Pear Therapeutics to Participate in BTIG Biotech Conference and Stifel Healthcare Conference
Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced its participation in the BTIG Biotech Conference and the Stifel Healthcare Conference. Details include:
- Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will speak at the BTIG Biotech Conference on October 25 at 9:30 a.m. at the Langham Hotel in New York.
- Corey McCann, M.D., Ph.D., President and CEO, will present at the Stifel Healthcare Conference on November 13, at 11:45 a.m. at the Lotte New York Palace Hotel.
Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.
About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics. We aim to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including mental health disorders, severe insomnia, and multiple sclerosis. Our lead product, reSET®, treats Substance Use Disorder (SUD) and was the first prescription digital therapeutic to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O™, for the treatment of Opioid Use Disorder (OUD), is currently under FDA review with Breakthrough Designation. For more information, visit us at www.peartherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005205/en/